Why ResMed Inc. (ASX:RMD) is one of the best growth stocks on the ASX 200

Sleep treatment specialist ResMed Inc.‘s (ASX: RMD) share price has risen 34% over the last 12 months, comfortably outperforming the broader market’s loss of 2%. The ASX 200 listed scrip has delivered another excellent quarterly earnings report surpassing the consensus estimate from analysts on both the top and bottom line.

Another great quarter

The September quarter has traditionally been the company’s weakest quarter. However, last week’s quarterly earnings report revealed that the company is continuing to effectively implement its growth strategy and is on target to achieve its long-term goal of changing 20 million lives by 2020.

Revenue for the quarter grew by 12% over the prior corresponding period to US$588.3 million, beating the consensus estimate of US$574 million. ResMed has expanded its product portfolio with new masks and ongoing upgrades to its increasingly important digital health solution offerings that remain a key factor in driving revenue growth and differentiating the company from its competitors. Geographically, revenues rose by over double digits across all major markets with the highest growth of 25% coming from the company’s software as a service business.

ResMed also managed to deliver effective cost control for the quarter with selling, general and administrative expenses increasing by only 2% over the prior corresponding period. The company’s operating leverage continues to impress and resulted in income from operations rising 28% to US$144.1 million and non-GAAP earnings per share increasing 23% to 81 cents, beating the consensus estimate of 78 cents.

Foolish takeaway

Shareholders of the Australian listed scrip have profited from the weakness in the Australian dollar as the ASX listing represents a 1/10th interest in the NYSE scrip. With the Australian dollar falling from 78 US cents to 71 US cents in 2018, shareholders of the Australian scrip have seen a 34% rise in their holding versus the 23% increase in the NYSE scrip.

ResMed and other healthcare companies such as CSL Limited (ASX: CSL) and Cochlear Limited (ASX: COH) offer investors an opportunity for solid growth over the long-term that differs from the traditional large end of the Australian market that is skewed towards the large banks and other mature businesses. Of course, these companies do not come cheaply and some caution is warranted to avoid overpaying for growth.

In ResMed’s case, the company is trading for around 28 times estimated FY19 earnings and 25 times FY20 estimated earnings. Therefore on a valuation basis, I would view the stock as a hold at current prices but with a view to add on any significant weakness.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Tim Katavic owns shares of CSL Limited. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!